Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis.
BACKGROUND
Case reports and series have suggested an association between oral sodium phosphate bowel preparations and kidney injury. Results of analytic studies have been mixed.


METHODS
Systematic review and meta-analysis.


METHODS
Patients receiving sodium phosphate bowel preparations (or comparators) in anticipation of colonoscopy.


METHODS
Primary data reports of controlled studies of the effects of oral sodium phosphate versus comparator on kidney function.


METHODS
Receipt of oral sodium phosphate bowel purgative.


RESULTS
Random-effects pooled odds ratio for kidney injury in oral sodium phosphate-treated patients.


RESULTS
Seven studies met criteria for inclusion. Significant heterogeneity existed in the populations under study (colonoscopy indication, baseline kidney function, and demographics), methods used (control group and use of prophylactic hydration), definition of kidney injury used (timing and magnitude), and results observed. The pooled odds ratio for kidney injury in oral sodium phosphate-treated patients ranged from 1.08 (95% confidence interval, 0.71 to 1.62) to 1.22 (95% confidence interval, 0.77 to 1.92). No obvious study- or patient-level factors that explained interstudy heterogeneity were identified.


CONCLUSIONS
Few studies, each of limited quality.


CONCLUSIONS
Based on existing data, it is not possible to discern whether there is an association between receipt of oral sodium phosphate and kidney injury. Future investigation should be aimed at clarifying this association and examining the roles of prophylactic hydration and baseline kidney function on any imposed risk. Future work would be greatly enhanced by a standardized definition of incident kidney injury.
Brunelli
Steven M
SM
Renal, Electrolyte, and Hypertension Division and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. sbrunelli@partners.org
D000284:Administration, Oral; D002400:Cathartics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D010710:Phosphates / Q000008:administration & dosage / Q000009:adverse effects*
D002400:Cathartics; D010710:Phosphates; C018279:sodium phosphate